

SUPPLEMENTARY TABLES

Supplementary Table 1. Primer sequences.

Gene	Primer sequences
CYP1A1	Forward, 5'GGTTAACCATGACCGGGA ACT3' Reverse, 5'TGCCCAAACCAAAGAGAGTGA3'
CYP1A2	Forward, 5'ACATTCCCAAGGAGCGCTGTATCT3' Reverse, 5'GTCGATGGCCGAGTTGTTATTGGT3'
CYP1B1	Forward, 5'GTGGCTGCTCATCCTCTTTACC3' Reverse, 5'CCCACAACCTGGTCCA ACTC3'
P450 _{ssc}	Forward, 5'GACCAAGTTCAGCCTCATCC3' Reverse, 5'CTCCAGCCTTCAGTTCACAG3'
3 β -HSD	Forward, 5'TTGTCATCCACACTGCTGCT3' Reverse, 5'TGGCACACTTGCTTGAACAC3'
p16	Forward, 5'CCCAACGCCCCGA ACT3' Reverse, 5'GCAGAAGAGCTGCTACGTGAA3'
p21	Forward, 5'GGCAGACCAGCCTGACAGAT3' Reverse, 5'TTCAGGGTTTTCTCTTGCAGAAG3'
TNF- α	Forward, 5'GACGTGGA ACTGGCAGAAGAG3' Reverse, 5'TTGGTGGTTTGTGAGTGTGAG3'
IL-1 β	Forward, 5'TTCAGGCAGGCAGTATCACTC3' Reverse, 5'GAAGGTCCACGGGAAAGACAC3'
IL-6	Forward, 5'TAGTCCTTCCTACCCCAATTTCC3' Reverse, 5'TTGGTCCTTAGCCACTCCTTC3'
IL-8	Forward, 5'TCGAGACCATTTACTGCAACAG3' Reverse, 5'CATTGCCGGTGGAAATTCCTT3'
TGF- α	Forward, 5'GGAACCTGCCGTTTTTTGG3' Reverse, 5'CACAGCGAACACCCACGTA3'
TGF- β 1	Forward, 5'CTCCCGTGGCTTCTAGTGC3' Reverse, 5'GCCTTAGTTTTGGACAGGATCTG3'
IGF-1	Forward, 5'AAATCAGCAGCCTTCCA ACTC3' Reverse, 5'GCACTTCCTCTACTTGTGTTCTT3'
GAPDH	Forward, 5'CAGTGGCAAAGTGGAGATTGTTG3' Reverse, 5'CTCGCTCCTGGAAGATGGTGAT3'

Supplementary Table 2. Antibodies used in the study.

Antibodies	Manufacturer	Catalogue No.	Dilution
Anti-Iba1	Wako	019-19741	1:1000 for IHC
Anti- GFAP	Covance	SMI-21R-100	1:1000for IHC
Anti- GFAP	Covance	PCK-591P-100	1:2000 for IF
Anti-GS	MilliporeSigma	G2781	1:5000 for IF
Anti-P16	Santa Cruz Biotechnology	sc-1207	1:1000 for IF
Anti- γ H2AX	Abcam	ab26350	1:1000 for IF
Anti-PKA	Cell Signaling Technology	#5842	1:1000 for WB
Anti-p-PKA	Cell Signaling Technology	#5661	1:1000 for WB
Anti-GAPDH	Abcam	ab127428	1:5000 for WB